AU2018270408A1 - Methods of inhibiting aging and treating aging-related disorders - Google Patents

Methods of inhibiting aging and treating aging-related disorders Download PDF

Info

Publication number
AU2018270408A1
AU2018270408A1 AU2018270408A AU2018270408A AU2018270408A1 AU 2018270408 A1 AU2018270408 A1 AU 2018270408A1 AU 2018270408 A AU2018270408 A AU 2018270408A AU 2018270408 A AU2018270408 A AU 2018270408A AU 2018270408 A1 AU2018270408 A1 AU 2018270408A1
Authority
AU
Australia
Prior art keywords
aging
methods
treating
inhibiting
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018270408A
Other languages
English (en)
Inventor
Aharon Brodie
Chaya Brodie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exostem Biotec Ltd
Original Assignee
Exostem Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exostem Biotec Ltd filed Critical Exostem Biotec Ltd
Publication of AU2018270408A1 publication Critical patent/AU2018270408A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
AU2018270408A 2017-05-16 2018-05-16 Methods of inhibiting aging and treating aging-related disorders Abandoned AU2018270408A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506661P 2017-05-16 2017-05-16
US62/506,661 2017-05-16
PCT/IL2018/050538 WO2018211510A1 (en) 2017-05-16 2018-05-16 Methods of inhibiting aging and treating aging-related disorders

Publications (1)

Publication Number Publication Date
AU2018270408A1 true AU2018270408A1 (en) 2019-12-12

Family

ID=64273428

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018270408A Abandoned AU2018270408A1 (en) 2017-05-16 2018-05-16 Methods of inhibiting aging and treating aging-related disorders

Country Status (6)

Country Link
US (1) US20200188440A1 (en-20US4325121.pdf)
EP (1) EP3624817A4 (en-20US4325121.pdf)
JP (1) JP2020519668A (en-20US4325121.pdf)
AU (1) AU2018270408A1 (en-20US4325121.pdf)
CA (1) CA3064064A1 (en-20US4325121.pdf)
WO (1) WO2018211510A1 (en-20US4325121.pdf)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753779B (zh) * 2018-06-07 2021-12-14 天津农学院 牛lncRNA-133a及在牛骨骼肌卫星细胞增殖分化调控中的应用和验证方法
TWI722400B (zh) * 2019-03-18 2021-03-21 佛教慈濟醫療財團法人 間質幹細胞之胞外泌體及其用途
CN111218451B (zh) * 2020-02-05 2021-08-10 华中农业大学 一种提高猪肌肉量的方法
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
CN111593114B (zh) * 2020-05-29 2022-12-20 广东医科大学附属医院 miR-122及其抑制剂在预防/治疗放射性脑损伤中的应用
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
CN112089733B (zh) * 2020-11-05 2021-03-12 广东赛尔生物科技有限公司 一种改造的脐带干细胞在制备抗衰老的药物组合物或者保健品中的用途
CN112280742A (zh) * 2020-11-05 2021-01-29 北京欣颂生物科技有限公司 干细胞制备的抗衰老的药物组合物或者保健品
KR102523933B1 (ko) * 2021-05-03 2023-04-20 고려대학교 산학협력단 융모막 추출물로부터 분리된 엑소좀을 유효성분으로 포함하는 골형성 촉진용 약학적 조성물
CN113981074A (zh) * 2021-12-10 2022-01-28 石河子大学 一种与2型糖尿病相关的microRNA及其应用
JP2023167026A (ja) * 2022-05-11 2023-11-24 克昭 團 膵機能活性化剤、抗老化剤、２型糖尿病の治療薬または予防薬、医薬品、化粧品および食品または飲料
CN115044543A (zh) * 2022-08-17 2022-09-13 山东卓东生物科技有限公司 一种提高衰老人体来源肌肉干细胞活性的方法
CN116926072B (zh) * 2023-05-04 2024-03-08 广州飞来爱生命科技有限公司 一种抑制神经干细胞诱导分化方法及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8192988B2 (en) * 2004-10-22 2012-06-05 University Of Central Florida Research Foundation, Inc. Methods for increasing potency of adult mesenchymal stem cells
KR20120096793A (ko) * 2011-02-23 2012-08-31 (주)차바이오앤디오스텍 태반 유래 줄기세포를 포함한 면역반응억제용 조성물
JP6329911B2 (ja) * 2012-02-22 2018-05-23 ブレインステム バイオテック リミテッド 星状膠細胞作製のためのミクロｒｎａ
KR101555981B1 (ko) * 2013-05-01 2015-09-30 차의과학대학교 산학협력단 태반 유래 중간엽 줄기 세포, 또는 태반 유래 줄기세포로부터 유도된 신경 전구세포, 이를 포함하는 약학적 조성물, 질환 치료용 키트, 및 이를 이용하는 질환 치료방법
EP3004328A4 (en) * 2013-05-30 2016-12-07 Cells For Cells MESENCHYMAL STEM CELLS OF CHORIONIC ORIGIN, CONDITIONED MEDIUM AS AN ANGIOGENESIS INDUCER AND USE THEREOF FOR TREATMENT OF CARDIAC DEGENERATION
WO2015170347A2 (en) * 2014-05-09 2015-11-12 Reelabs Private Limited Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders
AU2015330855A1 (en) * 2014-10-09 2017-04-27 Celularity Inc. Placenta-derived adherent cell exosomes and uses thereof
CN104560869B (zh) * 2014-12-18 2018-02-23 江苏省北科生物科技有限公司 一种制备绒毛膜间充质干细胞的方法
US20160324898A1 (en) * 2015-05-04 2016-11-10 Stemedica International, Sa Compositions and methods for the treatment of alzheimer's disease
AU2017265937A1 (en) * 2016-05-16 2018-11-22 Exostem Biotec Ltd. Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
MX2019005127A (es) * 2016-11-03 2019-09-26 Exostem Biotec Ltd Poblaciones y productos de células madre mesenquimales y sus usos.

Also Published As

Publication number Publication date
JP2020519668A (ja) 2020-07-02
CA3064064A1 (en) 2018-11-22
EP3624817A4 (en) 2021-05-19
US20200188440A1 (en) 2020-06-18
EP3624817A1 (en) 2020-03-25
WO2018211510A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
AU2018270408A1 (en) Methods of inhibiting aging and treating aging-related disorders
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2021009673A (es) Moduladores de ror-gamma.
WO2017095944A8 (en) Methods and compositions relating to chondrisomes from blood products
WO2016172658A3 (en) Microbiome regulators and related uses thereof
WO2016033439A3 (en) Compositions and methods for the treating an inflammatory disease or disorder
TW201613901A (en) New compounds
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2015073587A3 (en) Synthetic membrane-receiver complexes
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CY1119615T1 (el) Διπλα εκλεκτικοι αναστολεις ρι3 δελτα και γαμμα κινασης
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
WO2016077639A3 (en) Nanovesicular therapies
WO2014151456A3 (en) Treatment of inflammatory diseases
WO2015143447A3 (en) Methods for treating neurological disorders
MX2017005578A (es) Métodos de administración de composiciones de amantadina.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018002318A (es) Proceso mejorado para producir fucoxantina y/o polisacaridos de microalgas.
MX370586B (es) Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes.
EP3773530A4 (en) RAPID IMPROVEMENT OF VASCULAR STATES BY ADMINISTRATION OF VITAMIN K
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period